TriLink BioTechnologies specializes in the development and manufacturing of innovative nucleic acid tools and services, particularly focusing on mRNA technologies. Their proprietary CleanCap® technology enhances the stability and efficacy of mRNA by providing a highly efficient capping solution, which is critical for mRNA's performance in therapeutic applications. TriLink offers a comprehensive range of services, including custom mRNA synthesis, analytical testing, and GMP-grade manufacturing, which supports clients throughout various stages of drug development—from research and discovery to clinical trials and commercial production. Their capabilities also extend to the synthesis of modified nucleotides and oligonucleotides, catering to diverse applications in research, diagnostics, and therapeutics.

In addition to mRNA synthesis, TriLink emphasizes the importance of analytical services to ensure the quality and integrity of nucleic acid products. Their in-house analytical capabilities include method development, quality control testing, and stability studies, which are essential for meeting regulatory requirements in the rapidly evolving landscape of mRNA therapeutics. With over 25 years of experience, TriLink has established itself as a trusted partner for leading pharmaceutical companies, providing scalable solutions that adapt to the needs of their clients while maintaining high standards of quality and compliance.

United States

TriLink BioTechnologies

California - South

California

TriLink BioTechnologies

Company Details